Passa al contenuto
Merck

Structural basis for pharmacological modulation of the TRPC6 channel.

eLife (2020-03-10)
Yonghong Bai, Xinchao Yu, Hao Chen, Daniel Horne, Ryan White, Xiaosu Wu, Paul Lee, Yan Gu, Sudipa Ghimire-Rijal, Daniel C-H Lin, Xin Huang
ABSTRACT

Transient receptor potential canonical (TRPC) proteins form nonselective cation channels that play physiological roles in a wide variety of cells. Despite growing evidence supporting the therapeutic potential of TRPC6 inhibition in treating pathological cardiac and renal conditions, mechanistic understanding of TRPC6 function and modulation remains obscure. Here we report cryo-EM structures of TRPC6 in both antagonist-bound and agonist-bound states. The structures reveal two novel recognition sites for the small-molecule modulators corroborated by mutagenesis data. The antagonist binds to a cytoplasm-facing pocket formed by S1-S4 and the TRP helix, whereas the agonist wedges at the subunit interface between S6 and the pore helix. Conformational changes upon ligand binding illuminate a mechanistic rationale for understanding TRPC6 modulation. Furthermore, structural and mutagenesis analyses suggest several disease-related mutations enhance channel activity by disrupting interfacial interactions. Our results provide principles of drug action that may facilitate future design of small molecules to ameliorate TRPC6-mediated diseases.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Anti-TRPC6 antibody produced in rabbit, affinity isolated antibody, lyophilized powder